tiprankstipranks
Trending News
More News >
GlaxoSmithKline plc (UK) (GB:GSK)
:GSK
UK Market
Advertisement

GlaxoSmithKline (GSK) Share Forecast & Price Target

Compare
1,007 Followers
See the Price Targets and Ratings of:

GSK Analyst Ratings

Hold
13Ratings
Hold
2 Buy
8 Hold
3 Sell
Based on 13 analysts giving stock ratings to
GlaxoSmithKline
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GSK Stock 12 Month Forecast

Average Price Target

1,574.50p
▲(12.71% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is 1,574.50p with a high forecast of 2,170.00p and a low forecast of 1,290.00p. The average price target represents a 12.71% change from the last price of 1,397.00p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1289":"1,289p","1730":"1,730p","2171":"2,171p","1509.5":"1,509.5p","1950.5":"1,950.5p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1574.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.57K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.29K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1289,1509.5,1730,1950.5,2171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1396.5,1456,1515.5,1575,1634.5,1694,1753.5,1813,1872.5,1932,1991.5,2051,2110.5,{"y":2170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1396.5,1410.1923076923076,1423.8846153846155,1437.576923076923,1451.2692307692307,1464.9615384615386,1478.6538461538462,1492.3461538461538,1506.0384615384614,1519.7307692307693,1533.423076923077,1547.1153846153845,1560.8076923076924,{"y":1574.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1396.5,1388.3076923076924,1380.1153846153845,1371.923076923077,1363.7307692307693,1355.5384615384614,1347.3461538461538,1339.1538461538462,1330.9615384615386,1322.7692307692307,1314.576923076923,1306.3846153846155,1298.1923076923076,{"y":1290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1460.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1595.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1470.49,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1371.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1310.96,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1315.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1373.02,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1449.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1451.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1445.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1517,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1412.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1396.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target2,170pAverage Price Target1,575pLowest Price Target1,290p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GB:GSK
TipRanks AITipRanks
Not Ranked
TipRanks
1,572p
Buy
12.53%
Upside
Reiterated
08/06/25
GlaxoSmithKline's overall stock score reflects strong financial performance and strategic initiatives, such as share buybacks and acquisitions, which enhance shareholder value. The technical indicators suggest a neutral market sentiment, while the valuation is fair with an attractive dividend yield. The earnings call highlights growth in specialty medicines, though challenges in vaccine sales and regulatory impacts are noted.
J.P. Morgan Analyst forecast on GB:GSK
James GordonJ.P. Morgan
J.P. Morgan
1,460p1,400p
Sell
0.21%
Upside
Reiterated
08/04/25
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Bernstein
2,290p
Buy
63.92%
Upside
Reiterated
08/01/25
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
Goldman Sachs Analyst forecast on GB:GSK
Rajan SharmaGoldman Sachs
Goldman Sachs
1,560p1,550p
Hold
10.95%
Upside
Reiterated
08/01/25
Goldman Sachs Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Barclays Analyst forecast on GB:GSK
Emily FieldBarclays
Barclays
1,450p
Hold
3.79%
Upside
Reiterated
08/01/25
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Deutsche Bank  Analyst forecast on GB:GSK
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
1,450p
Hold
3.79%
Upside
Reiterated
07/31/25
Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on GB:GSK
Elmar KrausDZ BANK AG
DZ BANK AG
Hold
Reiterated
07/31/25
Kepler Capital  Analyst forecast on GB:GSK
Nicolas PauillacKepler Capital
Kepler Capital
1,500p
Hold
7.37%
Upside
Reiterated
07/30/25
Kepler Capital Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
UBS
1,600p
Hold
14.53%
Upside
Reiterated
07/30/25
GlaxoSmithKline (GSK) Gets a Hold from UBS
Jefferies
1,450p
Hold
3.79%
Upside
Reiterated
07/30/25
GlaxoSmithKline (GSK) Gets a Hold from Jefferies
Bank of America Securities Analyst forecast on GB:GSK
Sachin JainBank of America Securities
Bank of America Securities
1,434p
Sell
2.65%
Upside
Reiterated
07/30/25
Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Earnings Concerns and Market Uncertainties
Shore Capital Analyst forecast on GB:GSK
Unknown AnalystShore Capital
Not Ranked
Shore Capital
2,000p
Buy
43.16%
Upside
Reiterated
07/30/25
Shore Capital Remains a Buy on GlaxoSmithKline (GSK)
Berenberg Bank Analyst forecast on GB:GSK
Kerry HolfordBerenberg Bank
Berenberg Bank
1,600p
Hold
14.53%
Upside
Reiterated
07/18/25
Berenberg Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Morgan Stanley Analyst forecast on GB:GSK
Sarita KapilaMorgan Stanley
Morgan Stanley
1,355p1,290p
Sell
-7.66%
Downside
Reiterated
07/18/25
GlaxoSmithKline Downgraded to Sell Amid Blenrep Sales Decline and Earnings Adjustments
HSBC
1,190p1,170p
Sell
-16.25%
Downside
Reiterated
04/28/25
GSK price target lowered to 1,170 GBp from 1,190 GBp at HSBCGSK price target lowered to 1,170 GBp from 1,190 GBp at HSBC
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GB:GSK
TipRanks AITipRanks
Not Ranked
TipRanks
1,572p
Buy
12.53%
Upside
Reiterated
08/06/25
GlaxoSmithKline's overall stock score reflects strong financial performance and strategic initiatives, such as share buybacks and acquisitions, which enhance shareholder value. The technical indicators suggest a neutral market sentiment, while the valuation is fair with an attractive dividend yield. The earnings call highlights growth in specialty medicines, though challenges in vaccine sales and regulatory impacts are noted.
J.P. Morgan Analyst forecast on GB:GSK
James GordonJ.P. Morgan
J.P. Morgan
1,460p1,400p
Sell
0.21%
Upside
Reiterated
08/04/25
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Bernstein
2,290p
Buy
63.92%
Upside
Reiterated
08/01/25
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
Goldman Sachs Analyst forecast on GB:GSK
Rajan SharmaGoldman Sachs
Goldman Sachs
1,560p1,550p
Hold
10.95%
Upside
Reiterated
08/01/25
Goldman Sachs Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Barclays Analyst forecast on GB:GSK
Emily FieldBarclays
Barclays
1,450p
Hold
3.79%
Upside
Reiterated
08/01/25
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Deutsche Bank  Analyst forecast on GB:GSK
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
1,450p
Hold
3.79%
Upside
Reiterated
07/31/25
Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on GB:GSK
Elmar KrausDZ BANK AG
DZ BANK AG
Hold
Reiterated
07/31/25
Kepler Capital  Analyst forecast on GB:GSK
Nicolas PauillacKepler Capital
Kepler Capital
1,500p
Hold
7.37%
Upside
Reiterated
07/30/25
Kepler Capital Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
UBS
1,600p
Hold
14.53%
Upside
Reiterated
07/30/25
GlaxoSmithKline (GSK) Gets a Hold from UBS
Jefferies
1,450p
Hold
3.79%
Upside
Reiterated
07/30/25
GlaxoSmithKline (GSK) Gets a Hold from Jefferies
Bank of America Securities Analyst forecast on GB:GSK
Sachin JainBank of America Securities
Bank of America Securities
1,434p
Sell
2.65%
Upside
Reiterated
07/30/25
Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Earnings Concerns and Market Uncertainties
Shore Capital Analyst forecast on GB:GSK
Unknown AnalystShore Capital
Not Ranked
Shore Capital
2,000p
Buy
43.16%
Upside
Reiterated
07/30/25
Shore Capital Remains a Buy on GlaxoSmithKline (GSK)
Berenberg Bank Analyst forecast on GB:GSK
Kerry HolfordBerenberg Bank
Berenberg Bank
1,600p
Hold
14.53%
Upside
Reiterated
07/18/25
Berenberg Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Morgan Stanley Analyst forecast on GB:GSK
Sarita KapilaMorgan Stanley
Morgan Stanley
1,355p1,290p
Sell
-7.66%
Downside
Reiterated
07/18/25
GlaxoSmithKline Downgraded to Sell Amid Blenrep Sales Decline and Earnings Adjustments
HSBC
1,190p1,170p
Sell
-16.25%
Downside
Reiterated
04/28/25
GSK price target lowered to 1,170 GBp from 1,190 GBp at HSBCGSK price target lowered to 1,170 GBp from 1,190 GBp at HSBC
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

1 Month
xxx
Success Rate
15/29 ratings generated profit
52%
Average Return
-0.67%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.72% of your transactions generating a profit, with an average return of -0.67% per trade.
3 Months
xxx
Success Rate
14/29 ratings generated profit
48%
Average Return
+0.07%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.28% of your transactions generating a profit, with an average return of +0.07% per trade.
1 Year
James GordonJ.P. Morgan
Success Rate
15/29 ratings generated profit
48%
Average Return
-2.15%
reiterated a sell rating 4 days ago
Copying James Gordon's trades and holding each position for 1 Year would result in 48.28% of your transactions generating a profit, with an average return of -2.15% per trade.
2 Years
xxx
Success Rate
14/29 ratings generated profit
48%
Average Return
-0.04%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 48.28% of your transactions generating a profit, with an average return of -0.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GSK Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
2
2
2
0
Buy
25
35
38
41
33
Hold
35
32
32
49
42
Sell
5
4
3
4
3
Strong Sell
4
4
5
6
6
total
69
77
80
102
84
In the current month, GSK has received 33 Buy Ratings, 42 Hold Ratings, and 9 Sell Ratings. GSK average Analyst price target in the past 3 months is 1,574.50.
Each month's total comprises the sum of three months' worth of ratings.

GSK Financial Forecast

GSK Earnings Forecast

Next quarter’s earnings estimate for GSK is 0.47p with a range of 0.41p to 0.52p. The previous quarter’s EPS was 0.45p. GSK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year GSK has Preformed in-line its overall industry.
Next quarter’s earnings estimate for GSK is 0.47p with a range of 0.41p to 0.52p. The previous quarter’s EPS was 0.45p. GSK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year GSK has Preformed in-line its overall industry.

GSK Sales Forecast

Next quarter’s sales forecast for GSK is 8.18B with a range of 8.02B to 8.37B. The previous quarter’s sales results were 7.52B. GSK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year GSK has Preformed in-line its overall industry.
Next quarter’s sales forecast for GSK is 8.18B with a range of 8.02B to 8.37B. The previous quarter’s sales results were 7.52B. GSK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year GSK has Preformed in-line its overall industry.

GSK Stock Forecast FAQ

What is GB:GSK’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline plc (UK)’s 12-month average price target is 1,574.50.
    What is GB:GSK’s upside potential, based on the analysts’ average price target?
    GlaxoSmithKline plc (UK) has 12.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GlaxoSmithKline plc (UK) a Buy, Sell or Hold?
          GlaxoSmithKline plc (UK) has a consensus rating of Hold, which is based on 2 buy ratings, 8 hold ratings and 3 sell ratings.
            What is GlaxoSmithKline plc (UK)’s share price target?
            The average share price target for GlaxoSmithKline plc (UK) is 1,574.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 2,170.00p ,and the lowest forecast is 1,290.00p. The average share price target represents 12.71% Increase from the current price of 1,397p.
              What do analysts say about GlaxoSmithKline plc (UK)?
              GlaxoSmithKline plc (UK)’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of GlaxoSmithKline plc (UK)?
                To buy shares of GB:GSK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis